NO310179B1 - Farmasöytisk preparat, samt anvendelse av dette til fremstilling av en oral v¶ske for behandling og/eller forebyggelseav bentap hos et individ som har problemer med å svelge - Google Patents

Farmasöytisk preparat, samt anvendelse av dette til fremstilling av en oral v¶ske for behandling og/eller forebyggelseav bentap hos et individ som har problemer med å svelge Download PDF

Info

Publication number: NO310179B1
Authority: NO; Norway
Prior art keywords: pharmaceutical preparation; preparation according; alendronate; liquid; aqueous solution
Prior art date: 1994-05-17

Application number

NO19964864A

Other languages

English (en)

Norwegian (no)

Other versions

NO964864L (no

NO964864D0 (no

Inventor

Gerald S Brenner

Ashok V Katdare

Denise Pretzer

Donna T Whiteford

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-17

Filing date

1996-11-15

Publication date

2001-06-05

1996-11-15 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

1996-11-15 Publication of NO964864L publication Critical patent/NO964864L/no

1996-11-15 Publication of NO964864D0 publication Critical patent/NO964864D0/no

2001-06-05 Publication of NO310179B1 publication Critical patent/NO310179B1/no

Links

206010065687 Bone loss Diseases 0.000 title claims abstract description 10
230000009747 swallowing Effects 0.000 title claims abstract description 9
239000000825 pharmaceutical preparation Substances 0.000 title claims description 27
238000002360 preparation method Methods 0.000 title claims description 23
238000011282 treatment Methods 0.000 title claims description 14
230000002265 prevention Effects 0.000 title claims description 6
239000012530 fluid Substances 0.000 title 1
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims abstract description 35
229940062527 alendronate Drugs 0.000 claims abstract description 35
239000007864 aqueous solution Substances 0.000 claims abstract description 14
239000000843 powder Substances 0.000 claims abstract description 14
239000006188 syrup Substances 0.000 claims abstract description 10
235000020357 syrup Nutrition 0.000 claims abstract description 10
239000007788 liquid Substances 0.000 claims description 15
239000000872 buffer Substances 0.000 claims description 12
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 11
239000008139 complexing agent Substances 0.000 claims description 10
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 8
208000001132 Osteoporosis Diseases 0.000 claims description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
208000010191 Osteitis Deformans Diseases 0.000 claims description 4
208000027868 Paget disease Diseases 0.000 claims description 4
208000027202 mammary Paget disease Diseases 0.000 claims description 4
238000001556 precipitation Methods 0.000 claims description 4
239000001509 sodium citrate Substances 0.000 claims description 4
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
235000016337 monopotassium tartrate Nutrition 0.000 claims description 3
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 3
KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 claims description 3
229940086065 potassium hydrogentartrate Drugs 0.000 claims description 3
239000008213 purified water Substances 0.000 claims description 3
NKAAEMMYHLFEFN-ZVGUSBNCSA-M sodium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound [Na+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O NKAAEMMYHLFEFN-ZVGUSBNCSA-M 0.000 claims description 3
150000003431 steroids Chemical class 0.000 claims description 3
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 claims 1
230000000069 prophylactic effect Effects 0.000 claims 1
239000000243 solution Substances 0.000 abstract description 6
238000002560 therapeutic procedure Methods 0.000 abstract description 3
239000002552 dosage form Substances 0.000 abstract 1
239000012669 liquid formulation Substances 0.000 abstract 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
210000000988 bone and bone Anatomy 0.000 description 9
239000006172 buffering agent Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000003755 preservative agent Substances 0.000 description 6
239000003381 stabilizer Substances 0.000 description 6
208000006386 Bone Resorption Diseases 0.000 description 5
230000024279 bone resorption Effects 0.000 description 5
239000003814 drug Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
239000000654 additive Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
229910052500 inorganic mineral Inorganic materials 0.000 description 4
239000011707 mineral Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
208000010392 Bone Fractures Diseases 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
-1 citrate Chemical compound 0.000 description 3
239000003086 colorant Substances 0.000 description 3
150000004696 coordination complex Chemical class 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
201000008482 osteoarthritis Diseases 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
108010011485 Aspartame Proteins 0.000 description 2
208000020084 Bone disease Diseases 0.000 description 2
208000004434 Calcinosis Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000006670 Multiple fractures Diseases 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
230000032683 aging Effects 0.000 description 2
239000000605 aspartame Substances 0.000 description 2
235000010357 aspartame Nutrition 0.000 description 2
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
229960003438 aspartame Drugs 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
238000004040 coloring Methods 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000008021 deposition Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000002997 osteoclast Anatomy 0.000 description 2
208000005368 osteomalacia Diseases 0.000 description 2
IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 2
IZUPJOYPPLEPGM-UHFFFAOYSA-M sodium;hydron;phthalate Chemical compound [Na+].OC(=O)C1=CC=CC=C1C([O-])=O IZUPJOYPPLEPGM-UHFFFAOYSA-M 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000008399 tap water Substances 0.000 description 2
235000020679 tap water Nutrition 0.000 description 2
230000007306 turnover Effects 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
201000002980 Hyperparathyroidism Diseases 0.000 description 1
208000000913 Kidney Calculi Diseases 0.000 description 1
206010029148 Nephrolithiasis Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
230000010256 bone deposition Effects 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
230000002308 calcification Effects 0.000 description 1
229940069078 citric acid / sodium citrate Drugs 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000000975 dye Substances 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
235000012738 indigotine Nutrition 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
230000030991 negative regulation of bone resorption Effects 0.000 description 1
229940100688 oral solution Drugs 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
GSFNWGKBQZDYCL-UHFFFAOYSA-N sodium 2-(3-hydroxy-5-sulfo-1H-indol-2-yl)-3-oxoindole-5-sulfonic acid Chemical compound [Na+].Oc1c([nH]c2ccc(cc12)S(O)(=O)=O)C1=Nc2ccc(cc2C1=O)S(O)(=O)=O GSFNWGKBQZDYCL-UHFFFAOYSA-N 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
PAYGMRRPBHYIMA-UHFFFAOYSA-N sodium;trihydrate Chemical compound O.O.O.[Na] PAYGMRRPBHYIMA-UHFFFAOYSA-N 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO19964864A 1994-05-17 1996-11-15 Farmasöytisk preparat, samt anvendelse av dette til fremstilling av en oral v¶ske for behandling og/eller forebyggelseav bentap hos et individ som har problemer med å svelge NO310179B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/245,289 US5462932A (en)	1994-05-17	1994-05-17	Oral liquid alendronate formulations
PCT/US1995/005926 WO1995031203A1 (fr)	1994-05-17	1995-05-12	Formulations d'alendronate liquide a absorption orale

Publications (3)

Publication Number	Publication Date
NO964864L NO964864L (no)	1996-11-15
NO964864D0 NO964864D0 (no)	1996-11-15
NO310179B1 true NO310179B1 (no)	2001-06-05

Family

ID=22926074

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19964864A NO310179B1 (no)	1994-05-17	1996-11-15	Farmasöytisk preparat, samt anvendelse av dette til fremstilling av en oral v¶ske for behandling og/eller forebyggelseav bentap hos et individ som har problemer med å svelge

Country Status (33)

Country	Link
US (1)	US5462932A (fr)
EP (1)	EP0759757B1 (fr)
JP (1)	JP4111536B2 (fr)
KR (1)	KR100372966B1 (fr)
CN (1)	CN1079672C (fr)
AT (1)	ATE222495T1 (fr)
AU (1)	AU691634B2 (fr)
CA (1)	CA2190148C (fr)
CO (1)	CO4600739A1 (fr)
CY (1)	CY2336B1 (fr)
CZ (1)	CZ285860B6 (fr)
DE (1)	DE69527842T2 (fr)
DK (1)	DK0759757T3 (fr)
DZ (1)	DZ1884A1 (fr)
ES (1)	ES2180646T3 (fr)
FI (1)	FI118296B (fr)
HR (1)	HRP950293B1 (fr)
HU (1)	HU220626B1 (fr)
IL (1)	IL113651A (fr)
MX (1)	MX9605660A (fr)
MY (1)	MY112285A (fr)
NO (1)	NO310179B1 (fr)
NZ (1)	NZ289231A (fr)
PL (1)	PL179634B1 (fr)
PT (1)	PT759757E (fr)
RU (1)	RU2176507C2 (fr)
SI (1)	SI0759757T1 (fr)
SK (1)	SK281098B6 (fr)
TW (1)	TW402501B (fr)
UA (1)	UA29505C2 (fr)
WO (1)	WO1995031203A1 (fr)
YU (1)	YU49354B (fr)
ZA (1)	ZA953960B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5780455A (en) *	1994-08-24	1998-07-14	Merck & Co., Inc.	Intravenous alendronate formulations
KR19980702210A (ko) *	1995-02-17	1998-07-15	폴락 돈나 엘	비척추골 골절의 위험률을 감소시키는 방법
CA2219354A1 (fr) *	1995-05-12	1996-11-14	Merck & Co., Inc.	Prevention des pertes de dnets par l'administration d'alendronate ou de ses sels
IL118422A0 (en) *	1995-06-02	1996-09-12	Merck & Co Inc	Use of alendronate for the prevention of osteoporosis
US5616571A (en) *	1995-06-06	1997-04-01	Merck & Co., Inc.	Bisphosphonates prevent bone loss associated with immunosuppressive therapy
CA2221416A1 (fr) *	1995-06-06	1996-12-12	Merck & Co., Inc.	Traitement par bisphosphonates de la deperdition osseuse associee a l'arthrite rhumatoide
US6100301A (en) *	1996-02-28	2000-08-08	Pfizer Inc	Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
IL120270A0 (en) *	1996-02-28	1997-06-10	Pfizer	Combination therapy to treat osteoporosis
CZ116999A3 (cs) *	1996-10-04	1999-09-15	Merck And Co., Inc.	Vodný tekutý farmaceutický prostředek
US6376477B2 (en)	1996-11-25	2002-04-23	Merck & Co., Inc.	Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US6376476B1 (en) *	1996-12-13	2002-04-23	Zymogenetics Corporation	Isoprenoid pathway inhibitors for stimulating bone growth
US6080779A (en) *	1996-12-13	2000-06-27	Osteoscreen, Inc.	Compositions and methods for stimulating bone growth
FI104901B (fi)	1997-10-20	2000-04-28	Leiras Oy	Uudet metyleenibisfosfonihappojohdannaiset
GB9802617D0 (en) *	1998-02-07	1998-04-01	Knoll Ag	Pharmaceutical formulation
US6331533B1 (en)	1998-11-16	2001-12-18	Merck & Co., Inc.	Method for inhibiting dental resorptive lesions
US6194469B1 (en) *	1998-12-11	2001-02-27	Board Of Trustees Operating Michigan State Univeristy	Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids
CN1372468A (zh) *	1999-06-02	2002-10-02	宝洁公司	羟乙磷酸二钠口服制剂
US6677320B2 (en) *	2000-01-20	2004-01-13	Hoffmann-La Roches Inc.	Parenteral bisphosphonate composition with improved local tolerance
US6468559B1 (en)	2000-04-28	2002-10-22	Lipocine, Inc.	Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
KR100863146B1 (ko)	2000-07-17	2008-10-14	아스텔라스세이야쿠 가부시키가이샤	경구 흡수 개선 의약 조성물
DE60111574T2 (de) *	2001-01-23	2006-05-11	Gador S.A.	Bisphosphonate enthaltende Zusammensetzungen zur Vorbeugung und/oder Heilung von metabolischen Knochenkrankheiten, Verfahren zu ihrer Herstellung und Benutzung dieser Zusammensetzungen
US7695535B2 (en)	2001-10-10	2010-04-13	River Basin Energy, Inc.	Process for in-situ passivation of partially-dried coal
US7537622B2 (en) *	2001-10-10	2009-05-26	Fmi Newcoal, Inc.	Process for drying coal
US8197561B2 (en)	2001-10-10	2012-06-12	River Basin Energy, Inc.	Process for drying coal
US20030139378A1 (en) *	2001-12-13	2003-07-24	Daifotis Anastasia G.	Liquid bisphosphonate formulations for bone disorders
HUP0402267A3 (en) *	2001-12-21	2007-05-29	Procter & Gamble	Method for treatment of bone disorders
KR20140021045A (ko) *	2002-05-10	2014-02-19	에프. 호프만-라 로슈 아게	골다공증 치료 및 예방용 비스포스폰산
ITTO20020406A1 (it) *	2002-05-13	2003-11-13	Chiesi Farma Spa	Formulazioni di bisfosfonati ad uso iniettabile.
US7041309B2 (en) *	2002-06-13	2006-05-09	Neuropro Technologies, Inc.	Spinal fusion using an HMG-CoA reductase inhibitor
GR1004331B (el) *	2002-10-07	2003-09-05	Verisfield (Uk) Ltd	Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
NZ536273A (en) *	2002-12-20	2007-08-31	Hoffmann La Roche	High dose ibandronate formulation
US20050101605A1 (en) *	2003-11-07	2005-05-12	Ahmed Salah U.	Oral liquid formulations of methotrexate
US20080286359A1 (en) *	2004-05-24	2008-11-20	Richard John Dansereau	Low Dosage Forms Of Risedronate Or Its Salts
US20080287400A1 (en) *	2004-05-24	2008-11-20	Richard John Dansereau	Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en)	2004-05-24	2010-01-12	The Procter & Gamble Company	Dosage forms of bisphosphonates
BRPI0511530A (pt) *	2004-05-24	2008-01-02	Procter & Gamble	formas de dosagem de bisfosfonatos
US7645460B2 (en) *	2004-05-24	2010-01-12	The Procter & Gamble Company	Dosage forms of risedronate
CN1997374A (zh) *	2004-06-23	2007-07-11	默克公司	雌激素受体调节剂
WO2006019843A1 (fr) *	2004-07-15	2006-02-23	Nanobac Life Sciences	Procedes et compositions pour l'administration de chelateurs de calcium, de biphosphonates et/ou de composes de citrate et leurs utilisations pharmaceutiques
WO2006020009A1 (fr) *	2004-07-23	2006-02-23	The Procter & Gamble Company	Dosage oral solide formant un bisphosphonate et contenant un agent chélateur
US8012949B2 (en) *	2004-10-08	2011-09-06	The Board Of Trustees Of The University Of Illinois	Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
EP1802641B8 (fr) *	2004-10-08	2012-03-07	The Board Of Trustees Of The University Of Illinois	Composes de bisphosphonate et methodes de traitement de maladies de resorption osseuse, de cancers, de douleurs osseuses, de troubles immunitaires et de maladies infectieuses
US7687482B2 (en) *	2006-03-17	2010-03-30	The Board Of Trustees Of The University Of Illinois	Bisphosphonate compounds and methods
US20060134190A1 (en) *	2004-12-16	2006-06-22	Banner Pharmacaps Inc.	Formulations of bisphosphonate drugs with improved bioavailability
WO2007095161A2 (fr) *	2006-02-14	2007-08-23	New York University	Méthodes et compositions pour traiter des troubles associés à une augmentation du renouvellement osseux et une ostéopénie
SI1894557T1 (sl) *	2006-09-04	2011-04-29	Gador Sa	Tekoči sestavek za preprečevanje in/ali zdravljenje različnih kostnih metabolnih bolezni, uporaba le-tega, ter postopek za pripravo le-tega
EA200900095A1 (ru) *	2006-11-21	2009-08-28	ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК.	Лекарственные формы бифосфонатов для ингаляции и способы их применения
US8974801B2 (en) *	2006-12-21	2015-03-10	Amphastar Pharmaceuticals Inc.	Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
US20090170815A1 (en) *	2007-12-28	2009-07-02	Roxane Laboratories Incorporated.	Alendronate oral liquid formulations
CN101932306A (zh) *	2008-02-05	2010-12-29	阿特维斯集团公司	阿仑膦酸盐制剂、其制备方法和使用方法
US20100034752A1 (en) *	2008-08-11	2010-02-11	Toru Hibi	Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
US8956426B2 (en)	2010-04-20	2015-02-17	River Basin Energy, Inc.	Method of drying biomass
US9057037B2 (en)	2010-04-20	2015-06-16	River Basin Energy, Inc.	Post torrefaction biomass pelletization
US9889225B2 (en) *	2010-08-20	2018-02-13	Kaohsiung Medical University	Method for bone formation by administering poly(lactic-co-glycolic acid) cross-linked alendronate
ES2716525T3 (es)	2010-12-06	2019-06-13	Effrx Pharmaceuticals Sa	Formulaciones de bisfosfonatos efervescentes estables con características de solubilización rápida
CN103070824B (zh) *	2013-01-24	2014-07-16	天津红日药业股份有限公司	一种含有伊班膦酸钠的注射液
EP3054980B1 (fr) *	2013-10-08	2019-09-04	InnoPharma, Inc.	Formulations liquides orales d'aprépitant

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1187828B (it) *	1985-05-24	1987-12-23	Gentili Ist Spa	Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
GB8618259D0 (en) *	1986-07-25	1986-09-03	Leo Pharm Prod Ltd	Pharmaceutical compositions
DE3822650A1 (de) *	1988-07-05	1990-02-01	Boehringer Mannheim Gmbh	Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) *	1989-06-09	1990-05-01	Merck & Co., Inc.	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
FI83421C (fi) *	1989-06-21	1991-07-10	Huhtamaeki Oy	Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
US5227506A (en) *	1989-09-06	1993-07-13	Merck & Co., Inc.	Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
CA2035179C (fr) *	1990-01-31	2001-08-14	Gerald S. Brenner	Composition pharmaceutique contenant des sels insolubles d'acides biphosphonique
US5356887A (en) *	1990-01-31	1994-10-18	Merck & Co., Inc.	Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) *	1990-06-20	1991-05-28	Merck & Co., Inc.	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) *	1991-12-17	1993-12-14	Merck & Co., Inc.	Prevention and treatment of periodontal disease with alendronate
RU2029550C1 (ru) *	1992-03-20	1995-02-27	Светлана Семеновна Родионова	Способ коррекции метаболизма костной ткани
FR2703590B1 (fr) *	1993-04-05	1995-06-30	Sanofi Elf	Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .

1994
- 1994-05-17 US US08/245,289 patent/US5462932A/en not_active Expired - Lifetime
1995
- 1995-05-08 IL IL11365195A patent/IL113651A/xx not_active IP Right Cessation
- 1995-05-09 TW TW084104572A patent/TW402501B/zh not_active IP Right Cessation
- 1995-05-11 MY MYPI95001236A patent/MY112285A/en unknown
- 1995-05-12 AU AU29010/95A patent/AU691634B2/en not_active Expired
- 1995-05-12 JP JP52977395A patent/JP4111536B2/ja not_active Expired - Fee Related
- 1995-05-12 ES ES95924570T patent/ES2180646T3/es not_active Expired - Lifetime
- 1995-05-12 DE DE69527842T patent/DE69527842T2/de not_active Expired - Lifetime
- 1995-05-12 MX MX9605660A patent/MX9605660A/es unknown
- 1995-05-12 EP EP95924570A patent/EP0759757B1/fr not_active Expired - Lifetime
- 1995-05-12 NZ NZ289231A patent/NZ289231A/en unknown
- 1995-05-12 SK SK1477-96A patent/SK281098B6/sk unknown
- 1995-05-12 DK DK95924570T patent/DK0759757T3/da active
- 1995-05-12 UA UA96124659A patent/UA29505C2/uk unknown
- 1995-05-12 KR KR1019960706447A patent/KR100372966B1/ko not_active Expired - Lifetime
- 1995-05-12 CZ CZ963367A patent/CZ285860B6/cs not_active IP Right Cessation
- 1995-05-12 RU RU96123917/14A patent/RU2176507C2/ru not_active IP Right Cessation
- 1995-05-12 AT AT95924570T patent/ATE222495T1/de active
- 1995-05-12 PT PT95924570T patent/PT759757E/pt unknown
- 1995-05-12 PL PL95320614A patent/PL179634B1/pl not_active IP Right Cessation
- 1995-05-12 CA CA002190148A patent/CA2190148C/fr not_active Expired - Fee Related
- 1995-05-12 HU HU9603162A patent/HU220626B1/hu not_active IP Right Cessation
- 1995-05-12 CN CN95193086A patent/CN1079672C/zh not_active Expired - Fee Related
- 1995-05-12 SI SI9530610T patent/SI0759757T1/xx unknown
- 1995-05-12 WO PCT/US1995/005926 patent/WO1995031203A1/fr not_active Ceased
- 1995-05-16 CO CO95020682A patent/CO4600739A1/es unknown
- 1995-05-16 DZ DZ950055A patent/DZ1884A1/fr active
- 1995-05-16 ZA ZA953960A patent/ZA953960B/xx unknown
- 1995-05-16 HR HR950293A patent/HRP950293B1/xx not_active IP Right Cessation
- 1995-05-17 YU YU31795A patent/YU49354B/sh unknown
1996
- 1996-11-15 NO NO19964864A patent/NO310179B1/no not_active IP Right Cessation
- 1996-11-15 FI FI964593A patent/FI118296B/fi not_active IP Right Cessation
2003
- 2003-03-03 CY CY0300019A patent/CY2336B1/xx unknown

Also Published As

Publication number	Publication date
FI964593A0 (fi)	1996-11-15
PL320614A1 (en)	1997-10-13
MY112285A (en)	2001-05-31
FI118296B (fi)	2007-09-28
NZ289231A (en)	1998-04-27
FI964593L (fi)	1996-11-15
CZ336796A3 (en)	1997-06-11
SI0759757T1 (en)	2002-12-31
ES2180646T3 (es)	2003-02-16
NO964864L (no)	1996-11-15
HRP950293A2 (en)	1997-04-30
PT759757E (pt)	2002-11-29
CY2336B1 (en)	2004-02-06
HK1009245A1 (en)	1999-05-28
HRP950293B1 (en)	2003-08-31
EP0759757B1 (fr)	2002-08-21
KR100372966B1 (ko)	2003-05-12
CA2190148A1 (fr)	1995-11-23
UA29505C2 (uk)	2000-11-15
EP0759757A1 (fr)	1997-03-05
HU220626B1 (hu)	2002-03-28
IL113651A (en)	1999-08-17
PL179634B1 (pl)	2000-10-31
DK0759757T3 (da)	2002-10-07
RU2176507C2 (ru)	2001-12-10
ATE222495T1 (de)	2002-09-15
CN1148341A (zh)	1997-04-23
DZ1884A1 (fr)	2002-02-17
AU2901095A (en)	1995-12-05
TW402501B (en)	2000-08-21
NO964864D0 (no)	1996-11-15
KR970703151A (ko)	1997-07-03
HU9603162D0 (en)	1997-01-28
SK147796A3 (en)	1997-07-09
CN1079672C (zh)	2002-02-27
IL113651A0 (en)	1995-08-31
MX9605660A (es)	1998-02-28
DE69527842T2 (de)	2003-04-10
HUT76317A (en)	1997-08-28
WO1995031203A1 (fr)	1995-11-23
ZA953960B (en)	1996-01-19
CZ285860B6 (cs)	1999-11-17
SK281098B6 (sk)	2000-11-07
CA2190148C (fr)	2006-02-14
JPH10504020A (ja)	1998-04-14
CO4600739A1 (es)	1998-05-08
JP4111536B2 (ja)	2008-07-02
US5462932A (en)	1995-10-31
YU49354B (sh)	2005-09-19
DE69527842D1 (de)	2002-09-26
AU691634B2 (en)	1998-05-21
YU31795A (sh)	1999-06-15

Legal Events

Date	Code	Title	Description
2015-05-26	MK1K	Patent expired

Publication	Publication Date	Title
EP0759757B1 (fr)	2002-08-21	Formulations d'alendronate liquide a absorption orale
MXPA96005660A (en)	1998-02-01	Oral liquid formulations of alendron
EP0833643B1 (fr)	2005-02-16	Formulations de sel de monosodium d'alendronate anhydre et leur utilisation pour le traitement des maladies osseuses
US5914323A (en)	1999-06-22	Intravenous alendronate formulations
US6008207A (en)	1999-12-28	Anhydrous alendronate monosodium salt formulations
AU723357B2 (en)	2000-08-24	Liquid alendronate formulations
US20010021705A1 (en)	2001-09-13	Disodium alendronate formulations
CA2376258A1 (fr)	2000-12-14	Preparations orales d'etidronate disodique
US20090029946A1 (en)	2009-01-29	Aqueous oral solution of bisphosphonic acid
HK1009245B (en)	2002-11-29	Oral liquid alendronate formulations
US20090170815A1 (en)	2009-07-02	Alendronate oral liquid formulations